Black Diamond Therapeutics Inc
NASDAQ:BDTX
Black Diamond Therapeutics Inc
Interest Income Expense
Black Diamond Therapeutics Inc
Interest Income Expense Peer Comparison
Competitive Interest Income Expense Analysis
Latest Figures & CAGR of Competitors
Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Black Diamond Therapeutics Inc
NASDAQ:BDTX
|
Interest Income Expense
$1.9m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Interest Income Expense
-$1.8B
|
CAGR 3-Years
11%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-18%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Interest Income Expense
-$663m
|
CAGR 3-Years
38%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-8%
|
|
Amgen Inc
NASDAQ:AMGN
|
Interest Income Expense
-$2.9B
|
CAGR 3-Years
-44%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
-16%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Interest Income Expense
$630.1m
|
CAGR 3-Years
93%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Interest Income Expense
$221.8m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
75%
|
CAGR 10-Years
N/A
|
See Also
What is Black Diamond Therapeutics Inc's Interest Income Expense?
Interest Income Expense
1.9m
USD
Based on the financial report for Dec 31, 2023, Black Diamond Therapeutics Inc's Interest Income Expense amounts to 1.9m USD.
What is Black Diamond Therapeutics Inc's Interest Income Expense growth rate?
Interest Income Expense CAGR 3Y
-22%
The average annual Interest Income Expense growth rates for Black Diamond Therapeutics Inc have been -22% over the past three years .